TrialMultiple sclerosis (Houndmills, Basingstoke, England)2022

A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.

Jeffrey A Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.